Olysio

RSS

Withdrawn

This medicine's authorisation has been withdrawn

simeprevir
MedicineHumanWithdrawn

Latvian is available via eTranslation, the European Commission's machine translation service.

Translate to Latvian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 1 May 2018, the European Commission withdrew the marketing authorisation for Olysio (simeprevir) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Janssen-Cilag International NV, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Olysio was granted marketing authorisation in the EU on 14 May 2014 for the treatment of chronic hepatitis C (CHC) in adult patients, in combination with other medicinal products. The marketing authorisation was initially valid for a 5-year period. 

The European Public Assessment Report (EPAR) for Olysio is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (631.17 KB - PDF)

Skatīt

español (ES) (545.76 KB - PDF)

Skatīt

čeština (CS) (612.79 KB - PDF)

Skatīt

dansk (DA) (544.06 KB - PDF)

Skatīt

Deutsch (DE) (549.52 KB - PDF)

Skatīt

eesti (ET) (542.55 KB - PDF)

Skatīt

ελληνικά (EL) (636.55 KB - PDF)

Skatīt

français (FR) (547.32 KB - PDF)

Skatīt

hrvatski (HR) (566.73 KB - PDF)

Skatīt

italiano (IT) (545.35 KB - PDF)

Skatīt

latviešu (LV) (612.55 KB - PDF)

Skatīt

lietuvių (LT) (573.19 KB - PDF)

Skatīt

magyar (HU) (607.91 KB - PDF)

Skatīt

Malti (MT) (615.5 KB - PDF)

Skatīt

Nederlands (NL) (545.49 KB - PDF)

Skatīt

polski (PL) (612.66 KB - PDF)

Skatīt

português (PT) (545.33 KB - PDF)

Skatīt

română (RO) (572.83 KB - PDF)

Skatīt

slovenčina (SK) (612.97 KB - PDF)

Skatīt

slovenščina (SL) (604.67 KB - PDF)

Skatīt

suomi (FI) (543.74 KB - PDF)

Skatīt

svenska (SV) (544.08 KB - PDF)

Skatīt

Product information

български (BG) (2.23 MB - PDF)

Skatīt

español (ES) (1.18 MB - PDF)

Skatīt

čeština (CS) (1.84 MB - PDF)

Skatīt

dansk (DA) (1.19 MB - PDF)

Skatīt

Deutsch (DE) (1.22 MB - PDF)

Skatīt

eesti (ET) (1.12 MB - PDF)

Skatīt

ελληνικά (EL) (2.33 MB - PDF)

Skatīt

français (FR) (1.14 MB - PDF)

Skatīt

hrvatski (HR) (1.22 MB - PDF)

Skatīt

italiano (IT) (1.12 MB - PDF)

Skatīt

latviešu (LV) (1.78 MB - PDF)

Skatīt

lietuvių (LT) (1.19 MB - PDF)

Skatīt

magyar (HU) (1.85 MB - PDF)

Skatīt

Malti (MT) (1.97 MB - PDF)

Skatīt

Nederlands (NL) (1.21 MB - PDF)

Skatīt

polski (PL) (1.9 MB - PDF)

Skatīt

português (PT) (1.2 MB - PDF)

Skatīt

română (RO) (1.23 MB - PDF)

Skatīt

slovenčina (SK) (1.87 MB - PDF)

Skatīt

slovenščina (SL) (1.86 MB - PDF)

Skatīt

suomi (FI) (1.09 MB - PDF)

Skatīt

svenska (SV) (1.16 MB - PDF)

Skatīt

Íslenska (IS) (1.17 MB - PDF)

Skatīt

norsk (NO) (1.2 MB - PDF)

Skatīt
Latest procedure affecting product information:PSUSA/00010255/201705
08/02/2018
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (494.22 KB - PDF)

Skatīt

español (ES) (472.79 KB - PDF)

Skatīt

čeština (CS) (486.06 KB - PDF)

Skatīt

dansk (DA) (473.7 KB - PDF)

Skatīt

Deutsch (DE) (473.71 KB - PDF)

Skatīt

eesti (ET) (473.48 KB - PDF)

Skatīt

ελληνικά (EL) (493.72 KB - PDF)

Skatīt

français (FR) (473.61 KB - PDF)

Skatīt

hrvatski (HR) (473.63 KB - PDF)

Skatīt

italiano (IT) (474.2 KB - PDF)

Skatīt

latviešu (LV) (487.42 KB - PDF)

Skatīt

lietuvių (LT) (474.24 KB - PDF)

Skatīt

magyar (HU) (487.25 KB - PDF)

Skatīt

Malti (MT) (486.95 KB - PDF)

Skatīt

Nederlands (NL) (472.89 KB - PDF)

Skatīt

polski (PL) (486.5 KB - PDF)

Skatīt

português (PT) (473.15 KB - PDF)

Skatīt

română (RO) (472.56 KB - PDF)

Skatīt

slovenčina (SK) (486.79 KB - PDF)

Skatīt

slovenščina (SL) (485.7 KB - PDF)

Skatīt

suomi (FI) (472.83 KB - PDF)

Skatīt

svenska (SV) (472.91 KB - PDF)

Skatīt

Íslenska (IS) (472.72 KB - PDF)

Skatīt

norsk (NO) (472.92 KB - PDF)

Skatīt

Product details

Name of medicine
Olysio
Active substance
simeprevir
International non-proprietary name (INN) or common name
simeprevir
Therapeutic area (MeSH)
Hepatitis C, Chronic
Anatomical therapeutic chemical (ATC) code
J05AE14

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Olysio is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients.

For hepatitis C virus (HCV) genotype specific activity.

Authorisation details

EMA product number
EMEA/H/C/002777
Marketing authorisation holder
Janssen-Cilag International NV

Turnhoutseweg 30
B-2340 Beerse
Belgium

Opinion adopted
20/03/2014
Marketing authorisation issued
14/05/2014
Withdrawal of marketing authorisation
01/05/2018
Revision
13

Assessment history

български (BG) (687.46 KB - PDF)

Skatīt

español (ES) (530.79 KB - PDF)

Skatīt

čeština (CS) (87.91 KB - PDF)

Skatīt

dansk (DA) (532.07 KB - PDF)

Skatīt

Deutsch (DE) (542.71 KB - PDF)

Skatīt

eesti (ET) (528.43 KB - PDF)

Skatīt

ελληνικά (EL) (698.83 KB - PDF)

Skatīt

français (FR) (530.89 KB - PDF)

Skatīt

hrvatski (HR) (572.64 KB - PDF)

Skatīt

italiano (IT) (538.07 KB - PDF)

Skatīt

latviešu (LV) (664.34 KB - PDF)

Skatīt

lietuvių (LT) (575.28 KB - PDF)

Skatīt

magyar (HU) (616.82 KB - PDF)

Skatīt

Malti (MT) (649.44 KB - PDF)

Skatīt

Nederlands (NL) (537.08 KB - PDF)

Skatīt

polski (PL) (648.48 KB - PDF)

Skatīt

português (PT) (538.2 KB - PDF)

Skatīt

română (RO) (576.84 KB - PDF)

Skatīt

slovenčina (SK) (631.52 KB - PDF)

Skatīt

slovenščina (SL) (650.63 KB - PDF)

Skatīt

suomi (FI) (528.94 KB - PDF)

Skatīt

svenska (SV) (536.57 KB - PDF)

Skatīt

This page was last updated on

Share this page